Lucid Diagnostics Files 8-K

TL;DR

Lucid Diagnostics filed a standard 8-K, no major news.

AI Summary

Lucid Diagnostics Inc. filed an 8-K on September 11, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing from Lucid Diagnostics Inc. serves as a routine update, indicating no immediate material changes or significant events requiring immediate disclosure.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no specific material events or financial disclosures that would indicate increased risk.

Key Players & Entities

• Lucid Diagnostics Inc. (company) — Registrant
• September 11, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, Par Value $0.001 Per Share LUCD The Nasdaq Stock Mar
• $1.00 — e Company's common stock, at a price of $1.00 per share, in its previously announced
• $26.9 million — ering, are expected to be approximately $26.9 million. The Company intends to use the net pro

Filing Documents

• form8-k.htm (8-K) — 43KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 19KB
• 0001493152-25-013046.txt ( ) — 249KB
• lucd-20250911.xsd (EX-101.SCH) — 3KB
• lucd-20250911_lab.xml (EX-101.LAB) — 33KB
• lucd-20250911_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2025 LUCID DIAGNOSTICS INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40901 82-5488042 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.001 Per Share LUCD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation FD Disclosure. On September 11, 2025, Lucid Diagnostics Inc. (the " Company ") issued a press release announcing the closing of the Offering (as defined below). The press release is attached to this Current Report as Exhibits 99.1 and is incorporated herein by reference. The information furnished under this Item 7.01, including the exhibit related thereto, shall not be deemed "filed" for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document. Item 8.01. Other Events. On September 11, 2025, the Company closed on the sale of 28,750,000 shares (the " Shares ") of the Company's common stock, at a price of $1.00 per share, in its previously announced underwritten offering to the public (the " Offering "). The Shares include 3,750,000 shares of the Company's common stock subject to the underwriters' option, which was exercised in full at the closing. The net proceeds from the Offering, after deducting the underwriting discount and other estimated expenses of the Offering, are expected to be approximately $26.9 million. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners and Maxim Group LLC acted as co-manager of the Offering. The Offering was made pursuant to the Company's existing shelf registration statement on Form S-3 (Registration No. 333-268560), which was filed with the Securities and Exchange Commission (" SEC ") on November 25, 2022 and declared effective by the SEC on December 6, 2022, a preliminary prospectus supplement thereto, dated September 9, 2025, filed with the SEC on September 9, 2025, and a final prospectus supplement thereto, dated September 10, 2025, filed with the SEC on September 10, 2025. Item 9.01. Financial (d) Exhibits: Exhibit No. Description 99.1 Press release announcing the closing. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2025 LUCID DIAGNOSTICS INC. By: /s/ Dennis McGrath Dennis McGrath Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR